AU1256501A - A method of treating substance addiction - Google Patents

A method of treating substance addiction Download PDF

Info

Publication number
AU1256501A
AU1256501A AU12565/01A AU1256501A AU1256501A AU 1256501 A AU1256501 A AU 1256501A AU 12565/01 A AU12565/01 A AU 12565/01A AU 1256501 A AU1256501 A AU 1256501A AU 1256501 A AU1256501 A AU 1256501A
Authority
AU
Australia
Prior art keywords
calcium channel
channel blocker
amlodipine
verapamil
felodipine
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU12565/01A
Other languages
English (en)
Inventor
Albert Shulman
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Individual
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GBGB9926218.0A external-priority patent/GB9926218D0/en
Priority claimed from GBGB9929595.8A external-priority patent/GB9929595D0/en
Application filed by Individual filed Critical Individual
Publication of AU1256501A publication Critical patent/AU1256501A/en
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/485—Morphinan derivatives, e.g. morphine, codeine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/32—Alcohol-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/36—Opioid-abuse

Landscapes

  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Addiction (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Neurology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Psychiatry (AREA)
  • Epidemiology (AREA)
  • Emergency Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
AU12565/01A 1999-11-06 2000-11-06 A method of treating substance addiction Abandoned AU1256501A (en)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
GBGB9926218.0A GB9926218D0 (en) 1999-11-06 1999-11-06 Composition and method for the treatment of drug abuse
GB9926218 1999-11-06
GBGB9929595.8A GB9929595D0 (en) 1999-12-16 1999-12-16 New composition and method for the treatment of drug abuse
GB9929595 1999-12-16
PCT/AU2000/001367 WO2001034161A1 (en) 1999-11-06 2000-11-06 A method of treating substance addiction

Publications (1)

Publication Number Publication Date
AU1256501A true AU1256501A (en) 2001-06-06

Family

ID=26316056

Family Applications (1)

Application Number Title Priority Date Filing Date
AU12565/01A Abandoned AU1256501A (en) 1999-11-06 2000-11-06 A method of treating substance addiction

Country Status (9)

Country Link
EP (1) EP1242093A1 (zh)
JP (1) JP2004508274A (zh)
KR (1) KR20020063180A (zh)
CN (1) CN1402638A (zh)
AU (1) AU1256501A (zh)
CA (1) CA2390101A1 (zh)
NO (1) NO20022157L (zh)
NZ (1) NZ518992A (zh)
WO (1) WO2001034161A1 (zh)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20050043345A1 (en) * 2003-08-22 2005-02-24 Pfizer Inc Pharmaceutical composition for the prevention and treatment of addiction in a mammal
CA2760825C (en) * 2009-06-03 2017-07-11 Marquette University Modulation of kcnq potassium channel activity for treatment of psychiatric disorders and the symptoms thereof
US20240139135A1 (en) * 2019-10-11 2024-05-02 The Trustees Of Indiana University Pregabalin for treatment of opioid use disorder

Also Published As

Publication number Publication date
CA2390101A1 (en) 2001-05-17
NZ518992A (en) 2004-02-27
CN1402638A (zh) 2003-03-12
NO20022157L (no) 2002-07-04
KR20020063180A (ko) 2002-08-01
JP2004508274A (ja) 2004-03-18
WO2001034161A1 (en) 2001-05-17
EP1242093A1 (en) 2002-09-25
NO20022157D0 (no) 2002-05-06

Similar Documents

Publication Publication Date Title
AU613993B2 (en) Pharmaceutical compositions
WO2001052851A1 (en) Methods for the treatment of substance abuse
US4661492A (en) Analgesic compositions
CA2314893C (en) Opioid agonist/antagonist combinations
EP0144243B1 (en) Analgesic compositions
US20030144271A1 (en) Methods for the treatment of substance abuse
US20040024006A1 (en) Opioid pharmaceutical compositions
US20020058673A1 (en) Opioid agonist/opioid antagonist/acetaminophen combinations
AU1529701A (en) Analgesic compositions containing buprenorphine
US20100168147A1 (en) Medicinal Compositions Comprising Buprenorphine And Naloxone
TWI325320B (en) Active ingredient combination for pharmacological addictive substance or intoxicant therapy
MXPA02003670A (es) Sales y bases de 17-(ciclopropilmetil)-4,5 alfa-epoxi-6-metilenomorfinan-3,14 diol para optimizar la homeostasis de dopamina durante la administracion de analgesicos.
NO309965B1 (no) Oralt farmasøytisk antihostepreparat
JPWO2008120562A1 (ja) 帯状疱疹後神経痛治療用錠剤および帯状疱疹後神経痛の治療方法
AU1256501A (en) A method of treating substance addiction
EP1404341B1 (de) Wirkstoff-kombination zur medikamentösen therapie der nikotinabhängigkeit
AU2001226574A1 (en) Methods for the treatment of substance abuse
EP1250136A1 (en) Methods for the treatment of substance abuse
AU2014201779A1 (en) Improved medicinal compositions comprising buprenorphine and naloxone